A recent study detailed how drug decriminalization did not increase the risk of overdose-related deaths.
Conducted by Oregon and Washington, a recent study showed how drug decriminalization was not an instigator in overdose-related deaths (1). Drug policy reform has become a hot topic throughout the US. States such as Washington and Oregon have either fully or partially decriminalized drug possession. The study looked at an overview on overdose-related deaths, one-year post-implementation. Results showed that previous thoughts that the two may be connected were proven wrong.
In February 2021, Oregon enacted Measure 110. This showed that the state was suffering from a significant drug problem and that the state needed to expand access for drug treatment (2). Washington also experienced a State Supreme Court decision with the State v. Blake which stated that their felony drug possession law was considered unconstitutional (3).
MyCannabis mentioned that the study detailed (1):
Through the study’s findings, it shows the impact drug decriminalization can have on public health, as well as the need for further discussion on drug policy reform. An important note to take on this research is to remember that the data was only reviewing the short-term effects of decriminalization and that further investigation into the medium- and long-term effects needs to be explored. Drug reform advocates (1) are hopeful that research such as the study from Oregon and Washington, will bring about new data and legislation which will benefit those incarcerated, as well as public health.
References
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
2 Commerce Drive
Cranbury, NJ 08512